References
- Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986: 256(20): 2823–8
- Brown MS, Goldstein JL. A receptor-mediated pathway for cholesterol homeostasis. Science 1986: 232(4746): 34–47
- Bilheimer DW, Grundy SM, Brawn MS, et al. Mevlnolin and colestipol stimulate receptor-mediated clearance of low density lipoprotein from plasma in familial hypercholesterolemia heterozygotes. Proc Natl Acad Sci USA 1983: 80(13): 4124–8
- Frick MH, Elo O, Haapa K, et al. Helsinki Heart Study. Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987: 317(20): 1237–45
- Fredrickson DS, Levy RI, Lees RS. Fat transport in lipoproteins: an integrated approach to mechanisms and disorders. N Engl J Med 1967: 276(4): 34–44, 94–103, 148–56. 215–24, 273–81
- Grundy SM, Vega GL. Fibric acids: effects on lipids and lipoprotein metabolism. Am J Med 1987: 83(Suppl 5B): 9–20
- Vega GL, Grundy SM. Gemfibrozil therapy in primary hypertriglyceridemia associated with coronary heart disease: effects on metabolism of low-density lipoproteins. JAMA 1985: 253(16): 2398–403
- Stewart JM, Packard CJ, Lorimer AR, et al. Effects of bezafibrate on receptor-mediated and receptor-independent low density lipoprotein catabolism in type II hyperlipoproteinemic subjects. Atherosclerosis 1982: 44(3): 355–65
- Malmendier CL, Delcroix C. Effects of fenofibrate on high and low density lipoprotein metabolism in heterozygous familial hypercholesterolemia. Atherosclerosis 1985: 55(2): 161–9
- Report from Committee of Principal Investigators: a co-operative trial in the primary prevention of ischaemic heart disease using Clofibrate. Br Heart J 1978: 40(Oct): 1068–118
- Knapp RR, Brown WV, Dujovne CA, et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med 1987: 83(Suppl 5B): 50–9
- Saku K, Gartside PS, Hynd BA, et al. Mechanism of action of gemfibrozil on lipoprotein metabolism. J Clin Invest 1985: 75(5): 1702–12
- Grundy SM, Ahrens EH Jr, Salen G, et al. Mechanisms of action of Clofibrate on cholesterol metabolism in patients with hyperlipidemia. J Lipid Res 1972: 13(4): 531–51
- Coronary Drag Project Research Group. Gallbladder disease as a side effect of drugs influencing lipid metabolism: experience in the Coronary Drug Project. N Engl J Med 1977: 296(21): 1185–90
- Report of the National Cholesterol Education Program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. Arch Intern Med 1988: 148(1): 36–69
- Lipid Research Clinics Program. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease. JAMA 1984: 251(3): 351–64
- Canner PL, Berge KG, Wenger NK, et al. Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin. J Am Coll Cardiol 1986: 8(6): 1245–55
- Hulley SB, Rosenman RH, Bawol RD, et al. Epidemiology as a guide to clinical decisions: the association between triglyceride and coronary heart disease. N Engl J Med 1980: 302(25): 1383–9
- Goldstein JL, Schrott HG, Hazzard WR, et al. Hyperlipidemia in coronary heart disease. II. Genetic analysis of lipid levels in 176 families and delineation of a new inherited disorder, combined hyperlipidemia. J Clin Invest 1973: 52(7): 1544–68
- Sniderman A, Wolfson C, Teng B, et al. Association of hyperapobetalipoproteinemia with endogenous hypertriglyceridemia and atherosclerosis. Ann Intern Med 1982: 97(6): 833–9
- Castelli WP. The triglyceride issue: a view from Framingham. Am Heart J 1986: 112(2): 432–7
- Grundy SM. Hypertriglyceridemia: mechanisms, clinical significance, and treatment. Med Clin North Am 1982: 66(2): 519–35